Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) led to lower number of new lesions per day compared with placebo; GRADE not reported.
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
One trial at high risk of bias compared clofazimine (n=23) with placebo (n=20). The number of individuals in the clofazimine group who had no further aphthous episodes from beginning treatment until completion at 6…
1 study · 43 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Clofazimine was associated with an increase in cutaneous adverse effects (skin pigmentation and drying) (Fisher's exact test P=0.015), but these were reported to be easily controlled.
1 study · 43 participants
GRADE not reported
Sucking cessation (short term) · Children with a non-nutritive sucking habit (digit or pacifier)
1 finding from 1 review
Christensen 1987 (20 participants) compared habit reversal (HR) with differential reinforcement of other behaviour (DRO): no statistically significant difference. Larsson 1972 (38 participants) compared positive with…
2 studies · 58 participants
GRADE not reported
Prosthesis success (10 years) · Partially edentulous patients (mandible) receiving FDPs; split-mouth, 10-year
1 finding from 1 review
Adjusted maximum ulcer size and adjusted maximum pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Tetracycline suspension (250 mg, held in mouth 2 minutes then… showed no clear difference in average number of new lesions per week compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.47 [-1.34, 0.40]
1 study
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Alveolar bone loss · Partially edentulous patients (mandible) receiving FDPs; split-mouth, 10-year
1 finding from 1 review
Denture-induced stomatitis · Residents of institutions for elderly people (nursing staff and residents took part in the education programme)
1 finding from 1 review
Schou 1989 (114 residents, unclear risk of bias): no difference in the prevalence of denture stomatitis between the groups.
1 study · 114 participants
GRADE not reported
Denture plaque · Residents of institutions for elderly people (nursing staff and residents took part in the education programme)
1 finding from 1 review
One study (Schou 1989), at unclear risk of bias and analysing 114 residents, provided insufficient evidence to determine whether denture plaque scores are lower when educating residents or nursing staff without…
1 study · 114 participants
GRADE not reported
Oral health-related behaviour (denture cleaning habits) · Residents of institutions for elderly people (nursing staff and residents took part in the education programme)
1 finding from 1 review
Schou 1989 (114 residents, unclear risk of bias): the number of residents reporting correct denture cleaning habits increased, but not significantly compared to baseline (baseline N = 28; follow-up N = 38).
1 study · 114 participants
GRADE not reported
Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF5 Dietary supplements vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated dietary supplement; 628 participants (12 RCTs); very low. Subgroups: ALA without…
12 studies · 628 participants
Very low
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · benzydamine hydrochloride
SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
4 studies · 150 participants
Very low
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
2 findings from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review